CharalambosIAndreadisMD

Oncology • San Francisco, CA

Hematologic Oncology

UCSF BMT

Join to view full profile

Dr. Andreadis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Andreadis' full profile

Already have an account?

Office
505 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-476-4029

Fax+1 415-353-2467

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2001
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998

Certifications & Licensure

CA State Medical License 2008 - 2025
PA State Medical License 2001 - 2008
NY State Medical License 2004 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
Completed
Phase 1
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia Start of enrollment: 2011 Mar 01
Completed
Phase 1, Phase 2
Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck Start of enrollment: 2008 Mar 01
Unknown status
Phase 2
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Start of enrollment: 2012 Jan 01
Completed
Phase 1
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2012 May 25
Completed
Phase 2
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Start of enrollment: 2015 May 01
Terminated
Phase 1
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2015 May 05
Completed
Phase 1
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 Jun 13
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi
Journal of Clinical Oncology. 2024-10-20
20 citations
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad
Blood. 2024-04-25
11 citations
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter...
Michael Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning
Journal of Clinical Oncology. 2024-04-01

Abstracts/Posters

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Junior Faculty Career-Development Session
60th American Society of Hematology Annual Meeting - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all